06.Issue 02 february 24 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 11, Issue : 02, February – 2024

Title:

A REVIEW ON FALLOPIAN TUBE CARCINOMA

Authors :

Dr. Chandra Sekhara Rao Baru, Naren Kumar Barigela , Jajala Yeshwanth ,Avanthika Barigela , Gurram Teja

Abstract :

Primary fallopian tube cancer is an uncommon condition that is challenging to treat. It is frequently included with primary ovarian and peritoneal carcinomas under the general heading of epithelial ovarian cancer. According to more recent data, ovarian epithelial malignancies may have their origins in a precursor in the fallopian tube. Platinum-based chemotherapy and surgical cytoreduction constitute the cornerstones of treatment. The ideal time for surgery and the best method for administering chemotherapy are hotly contested topics. Conventional intravenous regimens that are administered once every three weeks are contrasted with intraperitoneal and dose-dense regimens. Despite the ongoing discussions surrounding this topic, new targeted treatments have surfaced, such as bevacizumab and inhibitors of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP). Patients with BRCA1/2 gene mutations benefit most from PARP medicines, and using them has been demonstrated to increase patient survival. This article reviews the etiology, pathophysiology, symptoms, diagnosis and treatment of the disease.
Keywords: Fallopian tube carcinoma, high grade serous cancers, serous tubal intraepithelial carcinomas, Epithelial ovarian carcinoma (EOC).

Cite This Article:

Please cite this article in press Chandrasekhara Rao Baru et al A Review On Fallopian Tube Carcinoma, Indo Am. J. P. Sci, 2024; 11 (02).

Number of Downloads : 10

References:

1. Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. Cancer. 2000;89:207684.
2. Schink J, Lurain J. Rare gynecological malignancies. Curr Opin Obstet Gynecol. 1991;3:7890.
3. Sedlis A. Primary carcinoma of the fallopian tube. Obstet Gynecol Surv 1961;16:209–226.
4. Semrad N, Watring W, Fu YS et al. Fallopian tube adenocarcinoma: common extraperitoneal recurrence. Gynecol Oncol 1986;24:230–235.
5. Roberts JA, Lifshitz S. Primary adenocarcinoma of the fallopian tube. Gynecol Oncol 1982;13:301–308
6. Raju KS, Barker GH, Wiltshaw E. Primary carcinoma of the fallopian tube. Report of 22 cases. Br J Obstet Gynaecol 1981;88:1124–1129.
7. Brown MD, Kohorn EI, Kapp DS et al. Fallopian tube carcinoma. Int J Radiat Oncol Biol Phys 1985;11:583–590.
8. Eddy GL, Copeland LJ, Gershenson DM et al. Second-look laparotomy in fallopian tube carcinoma. Gynecol Oncol 1984;19:182–186.
9. Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol 2013;169:155e61
10. Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilas G, et al. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 2009;115:97e101
11. Riska A, Alfthan H, Finne P, Jalkanen J, Sorvari T, Stenman UH, et al. Preoperative serum hCGbeta as a prognostic marker in primary fallopian tube carcinoma. Tumor Biol. 2006;27:439.
12. Gungor T, Keskin HL, Zergeroglu S, Keskin EA, Yalcin H, Aydogdu T, et al. Tuberculous salpingitis in two of five primary fallopian tube carcinomas. J Obstet Gynaecol. 2003; 23:1935
13. Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol. 2001;20:12832
14. Henderson SR, Harper RC, Salazar OM et al. Primary carcinoma of the fallopian tube: difficulties of diagnosis and treatment. Gynecol Oncol 1977;5:168–179.
15. Inal MM, Hanhan M, Pilanci B et al. Fallopian tube malignancies: experience of Social Security Agency Aegean Maternity Hospital. Int J Gynecol Cancer 2004;14:595–599
16. Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol 2001;20:128–132.
17. Tonin P, Moslehi R, Green R et al. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet 1995;95:545–550.
18. Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000;77: 319–320.
19. Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45–50.
20. Aziz S, Kuperstein G, Rosen B et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341–345
21. Aziz S, Kuperstein G, Rosen B et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341–345.
22. Hebert-Blouin MN, Koufogianis V, Gillett P et al. Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. Am J Obstet Gynecol 2002;186:53–54.
23.Jongsma AP, Piek JM, Zweemer RP et al. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol Pathol 2002;55:305–309.
24. Yanai-Inbar I, Silverberg SG. Mucosal epithelial proliferation of the fallopian tube: prevalence, clinical associations, and optimal strategy for histopathologic assessment. Int J Gynecol Pathol 2000;19:139–144.
25. Jacobs AJ, McMurray EH, Parham J et al. Treatment of carcinoma of the fallopian tube using cisplatin, doxorubicin, and cyclophosphamide. Am J Clin Oncol 1986;9:436–439.
26. Paley PJ, Swisher EM, Garcia RL et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80:176–180.
27. Baekelandt M, Kockx M, Wesling F et al. Primary adenocarcinoma of the fallopian tube. Review of the literature. Int J Gynecol Cancer 1993;3:65–71.
28. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3–9.
29. Katabuchi H, Okamura H. Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Med Electron Microsc. 2003;36(2):74–86
30. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371−1382
31. Chene G, Dauplat J, Radosevic-Robin N, Cayre A, Penault-Llorca F. Tu-be or not tu-be: that is the question … about serous ovarian carcinogenesis. Crit Rev Oncol Hematol. 2013;88(1):134–143
32. Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2012;119 Suppl 2: S118–S129.
33. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5(1):
34. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):
35. Katabuchi H, Okamura H. Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis. Med Electron Microsc. 2003;36(2):74–86.
36. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–169.
37. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3–9.
38. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989;35:236–239.
39. Hidaka T, Nakamura T, Shima T et al. Cerebral metastasis from a primary adenocarcinoma of the fallopian tube. Gynecol Oncol 2004;95:260–263.
40.Boutselis JG, Thompson JN. Clinical aspects of primary carcinoma of the Fallopian tube: a clinical study of 14 cases. Am J Obstet Gynecol 1971;111:98–101.
41.Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am 1978;58:121–129.
42.Blaustein A. Tubal adenocarcinoma coexistent with other genital neoplasms. Obstet Gynecol 1963;21:62–66.
43.Ross WM, Ward CV, Lindsay CC. Primary carcinoma of the fallopian tube. A report of 8 cases. Am J Obstet Gynecol 1962;83:425–429.
44.Markman M, Zaino R, Busowski J et al. Carcinoma of the fallopian tube. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: JB Lippincott Co, 1992:78
45 .Henderson SR, Harper RC, Salazar OM et al. Primary carcinoma of the fallopian tube: difficulties of diagnosis and treatment. Gynecol Oncol 1977;5:168–179.
46 .Ajithkumar TV, Minimole AL, John MM et al. Primary fallopian tube carcinoma. Obstet Gynecol Surv 2005;60:247–252.
47. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374(9698):1371−1382.
48. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer. 2003;13(6):735–740.
49. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer. 2003;13(6):735–740.
50. Katsumata N, Yasuda M, Takahashi F, et al; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331–1338.
51. Vasey PA, Jayson GC, Gordon A, et al; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–1691.